The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study

What Was Tested

This controlled clinical trial paper looks at Exenatide.

Therefore, the researchers aimed to assess the effect of exenatide on bile acids (BAs) and investigate the role of BAs in the glycemic control effect of exenatide.

FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.

Why It Was Studied

Registered in March 11, 2020 - Retrospectively registered.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Thirty-eight newly diagnosed T2DM participants without glucose-lowering drugs intake were recruited.

Then exenatide were applied to the T2DM participants for 12 weeks.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Exenatide study would be practical.

The timeline in the abstract includes 12 weeks.

Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline.

What Was Measured

The subject headings attached to it are Bile Acids and Salts, Diabetes Mellitus, Type 2, Exenatide, Fasting, Hypoglycemic Agents and Pilot Projects.

Author keywords: Glycemic control and Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a pilot study of Exenatide over 12 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (BMC pharmacology & toxicology), a journal based in England.

More context: the Exenatide compound page, all human trials.